萨诺迪在2012年初推荐新版Lantus进入后期发展

虽然兰花（Sanofi的胰岛素冰柱）是目前基底胰岛素的标准，但公司仍在投资显着的努力，以发展更好的长效胰岛素。在临床试验中，Novo Nordisk的新胰岛素称为Degludec在植物中提供了类似的改善作为兰花，具有较少的低血糖和更柔软的给药。上个月在美国和欧洲上个月提交了Degludec，在美国和欧洲，在2012年下半年潜在批准（见）纽诺文在诽谤＃37）。Lilly正在开发自己的胰岛素胰岛素版本，并暗示它可能比兰花更安全和/或更有效。此外，莉莉还在开发自己的新胰岛素。该公司目前正在为其胰岛素的胰岛素产品招募两阶段3次试验，并逐年开始为其新的基础胰岛素进行3阶段试验，如果一切都按计划批准两种产品。Earlier this month, Sanofi announced that it will be advancing a new version of Lantus into phase 3 trials in early 2012, which by our estimates would place approval as early as 2014 if all goes accordingly – before Lantus’ patents expire in 2015 in the US. The company has disclosed very few details about the new formulation, but emphasized that it will have a different clinical profile than Lantus – whether this means it will have a longer duration of action, have improved stability or less hypoglycemia, enable more flexible dosing, or provide some other novel feature remains to be seen. Exciting times ahead for those using basal insulin – improved options appear to be well along their way. –VW